TAL Education Group header image

TAL Education Group

TAL

Equity

ISIN null / Valor 11869921

New York Stock Exchange, Inc (2026-06-05)
USD 9.56-1.65%

TAL Education Group
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

TAL Education Group is a Beijing‑based provider of K–12 educational services in China, operating both a network of physical learning centers and online platforms that deliver instruction in core academic subjects (notably Chinese, mathematics and English), test preparation and supplemental programs; it also develops curricula, digital learning tools and teacher-training services and earns revenue from tuition, subscriptions and educational materials. The company combines classroom instruction with live and recorded online classes and has invested in adaptive learning and other education technologies to support personalized learning and content distribution. As one of the larger players in China’s after‑school tutoring market, TAL has been reshaping its business mix and expanding technology and non‑core offerings in response to recent regulatory reforms affecting private K–12 tutoring.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (16.05.2026):

TAL Education Group — Fourth fiscal quarter and fiscal year ended February 28, 2026: TAL reported strong revenue and profit recovery. For Q4 FY2026 net revenues were US$802.4 million (up 31.5% YoY) and GAAP net income attributable to TAL was US$244.8 million (versus a US$7.3 million loss in Q4 FY2025), with basic and diluted net income per ADS of US$0.44. For the full fiscal year 2026, net revenues were US$3,008.9 million (up 33.7% YoY) and GAAP net income attributable to TAL was US$530.8 million, with basic and diluted net income per ADS of US$0.93 and US$0.92 respectively.

Revenue

Q4 FY2026 net revenues: US$802.4M (+31.5% YoY). FY2026 net revenues: US$3,008.9M (+33.7% YoY), showing broad top-line growth across the year.

Profitability (GAAP)

Q4 FY2026 income from operations: US$72.5M (vs a US$16.0M loss in Q4 FY2025). Q4 GAAP net income attributable to TAL: US$244.8M. FY2026 GAAP income from operations: US$276.0M and GAAP net income attributable to TAL: US$530.8M.

Non‑GAAP results

Q4 non‑GAAP income from operations (ex‑share‑based comp.): US$82.2M (vs non‑GAAP loss US$1.7M prior year). Q4 non‑GAAP net income attributable: US$254.5M; non‑GAAP net income per ADS: US$0.46 (basic), US$0.45 (diluted). FY2026 non‑GAAP net income: US$573.8M; non‑GAAP net income per ADS: US$1.00 (basic), US$0.99 (diluted).

Margins and costs

Q4 gross profit rose to US$427.2M and gross margin improved to 53.2% (from 52.0%). Q4 operating costs and expenses increased 16.6% YoY to US$729.9M; FY operating costs rose 21.3% to US$2,732.9M. Share‑based compensation allocated to operating costs declined (Q4: US$9.8M vs US$14.3M prior year; FY: US$43.1M vs US$64.9M).

Other income and impairments

Q4 other income jumped to US$275.0M (driven by fair‑value fluctuations of certain investments) vs US$13.0M prior year; Q4 impairment loss on long‑term investments was US$41.4M (vs US$4.2M). FY2026 other income: US$390.2M; impairment loss FY: US$42.8M.

Cash, liquidity and deferred revenue

As of Feb 28, 2026, cash, cash equivalents and short‑term investments totaled US$3,239.3M (cash & equivalents US$1,523.9M; short‑term investments US$1,715.4M), down from US$3,618.4M a year earlier. Deferred revenue rose to US$882.2M (from US$671.2M).

Cash flow

Q4 net cash used in operating activities: US$215.0M. FY2026 net cash provided by operating activities: US$601.5M. Investing and financing flows narrowed FY cash outflows (investing down vs prior year; financing large outflow partly from share repurchase authorization timing).

Capital return & management

Board authorized a new US$600M share repurchase program on July 28, 2025; between Jan 29 and Apr 22, 2026 the company repurchased 101,371 shares for ~US$3.3M. Management change: CTO Mi Tian stepped down to Senior VP on April 22, 2026 to focus on select technology initiatives.

Summarized from source with an LLMView Source

Key figures

-8.95%1Y
58.3%3Y
-68.1%5Y

Performance

45.2%1Y
58.4%3Y
97.7%5Y

Volatility

Market cap

4406 M

Market cap (USD)

Daily traded volume (Shares)

3,136,087

Daily traded volume (Shares)

1 day high/low

9.735 / 9.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Option Care Health Inc
Option Care Health Inc Option Care Health Inc Valor: 52359365
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.19%USD 20.51
Alkermes PLC
Alkermes PLC Alkermes PLC Valor: 13920929
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.34%USD 42.80
Galapagos NV
Galapagos NV Galapagos NV Valor: 2130343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.33%EUR 24.40
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1103058
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.28%GBP 11.47
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.93%SEK 96.15
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.68%CHF 93.98
Medacta Group Ltd
Medacta Group Ltd Medacta Group Ltd Valor: 46852522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.73%CHF 138.80
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.62%USD 238.57
Legend Biotech Corporation
Legend Biotech Corporation Legend Biotech Corporation Valor: 54834759
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.62%USD 32.62
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.61%EUR 70.00